Surveillance of the overall use of antimicrobial drugs in humans over a 5 year period (1997–2001) in Kenya

spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. Journal of Antimicrobial Chemotherapy 53, 669–74. 4. Fluit, A., Schmitz, F. J., Verhoef, J. et al. (2004). In vitro activity of daptomycin against Gram-positive European clinical isolates with defined resistance determinants. Antimicrobial Agents and Chemotherapy 48, 1007–11. 5. Duh, R. W., Singh, K. V., Malathum, K. et al. (2001). In vitro activity of 19 antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an ace gene probe from Enterococcus faecalis for species identification. Microbial Drug Resistance 7, Suppl.1, 39–46. 6. Novais, C., Coque, T. M., Sousa, J. C. et al. (2002). The community and the environment: insights about recent epidemiology of Enterococcus resistance in Portugal. In Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract 1117, p. 101. American Society for Microbiology, Washington, DC, USA. 7. Dukta-Malen, S., Evers, S. & Courvalin, P. (1995). Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. Journal of Clinical Microbiology 33, 24–7.